Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Starling Oncology, Inc.
Report date June 10, 2022 · Filed June 14, 2022
Jointly reported with Jimmy Holdings, Inc.
Section 16 reporting ended · disclosed 2022-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2028-09-18 | IndirectSee Footnote | 296,075 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Sale · Disposed 300,000 · Balance 296,075 F1: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer. F2: Held by Dr. Agajanian's spouse. The reporting persons disclaim beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer.
F2: Held by Dr. Agajanian's spouse. The reporting persons disclaim beneficial ownership of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2022 Filed Jun 14, 2022 19:12 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleStock Option (right to buy) · Derivative | 300,000 | $5.15 Strike: $0.85 | $1,545,000.00 |
DisclosureSEC source: 0001437749-22-015003 · rdgdoc.xml · derivative · entry 1 Agajanian Richy · CIK 0001895577 · 10% owner Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 296,075 Underlying: Class A Common Stock · 300,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer. F1 · balance_after: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer. F2 · ownership.nature: Held by Dr. Agajanian's spouse. The reporting persons disclaim beneficial ownership of these securities. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:57 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleClass A Common Stock | 253,435 | $6.00 | $1,520,610.00 |
DisclosureSEC source: 0001437749-22-012393 · rdgdoc.xml · nonDerivative · entry 2 Agajanian Richy · CIK 0001895577 · 10% owner Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 253,436 F2 · ownership.nature: Held by Agajanian Holdings LLC. The membership interests of Agajanian Holdings LLC are held by three trusts each of which Richy Agajanian is a trustee or co-trustee and in such capacity has or shares voting and dispositive authority. The reporting persons disclaim beneficial ownership of these securities except to extent of Richy Agajanian's pecuniary interest as a result of being a beneficiary of one or more of the trusts. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:57 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleClass A Common Stock | 1,346,565 | $6.00 | $8,079,390.00 |
DisclosureSEC source: 0001437749-22-012393 · rdgdoc.xml · nonDerivative · entry 1 Agajanian Richy · CIK 0001895577 · 10% owner Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,295,688 F1 · ownership.nature: Held directly by Jimmy Holdings, Inc. and indirectly by Richy Agajanian, the sole holder of all of the outstanding capital stock of Jimmy Holdings, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.